Our results revealed that insulin resistance may have a negative effect on pathological complete response (pCR) following neoadjuvant therapy particularly with hormone-positive and Her-2 negative cases of non-diabetic breast cancer. This evidence concerns the gene ERBB2 and Insulin resistance.